Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapeutics for the treatment of Alzheimer's and other
neurodegenerative diseases. The company focuses on advancing a targeted immunotherapy drug candidate ACU193, which is in Phase I clinical-stage to target soluble amyloid-beta oligomers. Acumen Pharmaceuticals, Inc. was incorporated in 1996 and is based in Charlottesville, Virginia. The company trades on NMS exchange. The company headquarter is located in Charlottesville ,United States.
| Ticker | ABOS |
| Long Name | Acumen Pharmaceuticals, Inc. |
| Short Name | Acumen Pharmaceuticals, Inc. |